Expert Consensus
Copyright ©The Author(s) 2021.
World J Gastroenterol. Dec 21, 2021; 27(47): 8069-8080
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8069
Table 3 Evidence for systemic therapy plus local therapy in conversion therapy
Ref.
Treatment regimen
Number of patients, n (%)
Study results
Zhang et al[37], 2020TKI: Lenvatinib. PD-1 antibody: Pembrolizumab/Sintilimab/Toripalimab 33Success rate of conversion (imaging): 42.4%. Actual surgery rate following conversion: 30.3%
Li et al[40], 2017TACE + sorafenib142Second-stage resection rate following stage reduction: 14.8%
He et al[39], 2019HAIC + sorafenib125Surgical resection rate following conversion: 12.8%
He et al[41], 2018HAIC + sorafenib35Surgical resection rate following conversion: 14.3%
Zhang et al[42], 2021HAIC + TKI + PD-1 antibody (1, 7, and 17 patients used sorafenib, apatinib, and lenvatinib, respectively)25Surgical resection rate following conversion: 56.0%, 7 patients (28.0%) achieved pathologically complete remission
He et al[38], 2021Lenvatinib + toripalimab + HAIC71Surgical resection rate following conversion: 12.7%